References
- Greenberg PL, Stone RM, Al-Kali A, et al. Myelodysplastic syndromes, version 2.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2017;15(1):60–87. doi:https://doi.org/10.6004/jnccn.2017.0007.
- Ades L, Itzykson R, Fenaux P. Myelodysplastic syndromes. Lancet. 2014;383(9936):2239–2252. doi:https://doi.org/10.1016/S0140-6736(13)61901-7.
- National Cancer Institute Surveillance E, and End Results (SEER) Program. (2017). SEER Cancer Statistics Review 1975-2017.
- Kobbe G, Schroeder T, Haas R, et al. The current and future role of stem cells in myelodysplastic syndrome therapies. Expert Rev Hematol. 2018;11(5):411–422. doi:https://doi.org/10.1080/17474086.2018.1452611.
- National Comprehensive Cancer Network. (2020). NCCN Clinical practice guidelines in oncology - Myelodysplastic syndromes version 2.2020 [cited 2020 May 12]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/mds.pdf.
- US Food and Drug Administration. (2020). Prescribing information - DACOGEN® (decitabine) [cited 2020 May 8]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021790s023lbl.pdf.
- US Food and Drug Administration. (2020). Prescribing information - VIDAZA (azacitidine) [cited 2020 May 8]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/050794s032lbl.pdf.
- Scott LJ. Azacitidine: a review in myelodysplastic syndromes and acute myeloid leukaemia. Drugs. 2016;76(8):889–900. doi:https://doi.org/10.1007/s40265-016-0585-0.
- Killick SB, Carter C, Culligan D, et al. Guidelines for the diagnosis and management of adult myelodysplastic syndromes. Br J Haematol. 2014;164(4):503–525. doi:https://doi.org/10.1111/bjh.12694.
- Silverman LR, Demakos EP, Peterson BL, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: A study of the cancer and leukemia group B. J Clin Oncol. 2002;20(10):2429–2440. doi:https://doi.org/10.1200/jco.2002.04.117.
- Kantarjian H, Issa J-PJ, Rosenfeld CS, et al. Decitabine improves patient outcomes in myelodysplastic syndromes. Cancer. 2006;106(8):1794–1803. doi:https://doi.org/10.1002/cncr.21792.
- Cabrero M, Jabbour E, Ravandi F, et al. Discontinuation of hypomethylating agent therapy in patients with myelodysplastic syndromes or acute myelogenous leukemia in complete remission or partial response: retrospective analysis of survival after long-term follow-up. Leuk Res. 2015;39(5):520–524. doi:https://doi.org/10.1016/j.leukres.2015.03.006.
- Mukherjee S, Cogle CR, Bentley TG, et al. Treatment patterns among patients with myelodysplastic syndromes: observations of 1st-line therapy, discontinuation and the need of additional therapies. Blood. 2014;124(21):2598. doi:https://doi.org/10.1182/blood.V124.21.2598.2598.
- Demakos EP, Silverman LR, Lawrence ME, et al. Incidence and treatment of myelodysplastic syndrome in the US: treatment approaches, optimization of care and the need for additional therapeutic agents. Blood. 2014;124(21):1287. doi:https://doi.org/10.1182/blood.V124.21.1287.1287.
- Cogle CR, Mukherjee S, Bentley TG, et al. Healthcare resource utilization and costs among patients with myelodysplastic syndrome who failed 1st-line therapy. Blood. 2014;124(21):2627.
- Cogle CR, Kurtin SE, Bentley TG, et al. The incidence and health care resource burden of the myelodysplastic syndromes in patients in whom first-line hypomethylating agents fail. Oncologist. 2017;22(4):379–385. doi:https://doi.org/10.1634/theoncologist.2016-0211.
- Cogle CR. Incidence and burden of the myelodysplastic syndromes. Curr Hematol Malig Rep. 2015;10(3):272–281. doi:https://doi.org/10.1007/s11899-015-0269-y.
- Eek D, Krohe M, Mazar I, et al. Patient-reported preferences for oral versus intravenous administration for the treatment of cancer: a review of the literature. Patient Prefer Adherence. 2016;10:1609–1621. doi:https://doi.org/10.2147/PPA.S106629.
- Stewart KD, Johnston JA, Matza LS, et al. Preference for pharmaceutical formulation and treatment process attributes. Patient Prefer Adherence. 2016;10:1385–1399. doi:https://doi.org/10.2147/PPA.S101821.
- O'Neill VJ, Twelves CJ. Oral cancer treatment: developments in chemotherapy and beyond. Br J Cancer. 2002;87(9):933–937. doi:https://doi.org/10.1038/sj.bjc.6600591.
- Booth A, Bell T, Halhol S, et al. Using social media to uncover treatment experiences and decisions in patients with acute myeloid leukemia or myelodysplastic syndrome who are ineligible for intensive chemotherapy: patient-centric qualitative data analysis. J Med Internet Res. 2019;21(11):e14285. doi:https://doi.org/10.2196/14285.
- Prebet T, Fenaux P, Vey N, et al. Predicting outcome of patients with myelodysplastic syndromes after failure of azacitidine: validation of the North American MDS consortium scoring system. Haematologica. 2016;101(10):e427–e428. doi:https://doi.org/10.3324/haematol.2016.150714.